NASDAQ:CATB - Catabasis Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.8142 +0.04 (+5.17 %)
(As of 09/20/2018 08:57 AM ET)
Previous Close$0.7698
Today's Range$0.78 - $0.84
52-Week Range$0.61 - $3.78
Volume2.75 million shs
Average Volume1.19 million shs
Market Capitalization$54.69 million
P/E Ratio-0.65
Dividend YieldN/A
Beta0.59
Catabasis Pharmaceuticals logoCatabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) and malfunctioning of CF transmembrane conductance regulator, as well as for the clearance of pathogens, such as P. aeruginosa and B. cenocepacia; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases consisting of Friedreich's ataxia and amyotrophic lateral sclerosis. In addition, the company offers CAT-2000 compounds, which are SMART linker conjugates of nicotinic acid and EPA that are used for the treatment of nonalcoholic steatohepatitis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD. The company was founded in 2008 and is based in Cambridge, Massachusetts.

Receive CATB News and Ratings via Email

Sign-up to receive the latest news and ratings for CATB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CATB
CUSIPN/A
Phone617-349-1971

Debt

Debt-to-Equity RatioN/A
Current Ratio10.22
Quick Ratio10.22

Price-To-Earnings

Trailing P/E Ratio-0.65
Forward P/E Ratio-1.09
P/E GrowthN/A

Sales & Book Value

Annual Sales$500,000.00
Price / Sales115.68
Cash FlowN/A
Price / CashN/A
Book Value$0.51 per share
Price / Book1.60

Profitability

EPS (Most Recent Fiscal Year)($1.26)
Net Income$-27,360,000.00
Net MarginsN/A
Return on Equity-123.67%
Return on Assets-96.60%

Miscellaneous

Employees36
Outstanding Shares71,040,000
Market Cap$54.69 million

Catabasis Pharmaceuticals (NASDAQ:CATB) Frequently Asked Questions

What is Catabasis Pharmaceuticals' stock symbol?

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."

How were Catabasis Pharmaceuticals' earnings last quarter?

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) announced its quarterly earnings results on Friday, August, 10th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.03. View Catabasis Pharmaceuticals' Earnings History.

When is Catabasis Pharmaceuticals' next earnings date?

Catabasis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Catabasis Pharmaceuticals.

What price target have analysts set for CATB?

5 equities research analysts have issued 12-month target prices for Catabasis Pharmaceuticals' shares. Their predictions range from $1.50 to $7.00. On average, they anticipate Catabasis Pharmaceuticals' share price to reach $4.10 in the next twelve months. This suggests a possible upside of 403.6% from the stock's current price. View Analyst Price Targets for Catabasis Pharmaceuticals.

What is the consensus analysts' recommendation for Catabasis Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catabasis Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catabasis Pharmaceuticals.

Who are some of Catabasis Pharmaceuticals' key competitors?

Who are Catabasis Pharmaceuticals' key executives?

Catabasis Pharmaceuticals' management team includes the folowing people:
  • Ms. Jill C. Milne, Co-Founder, CEO, Pres & Director (Age 50)
  • Dr. Andrew J. Nichols, Chief Scientific Officer (Age 57)
  • Dr. Joanne M. Donovan, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 61)
  • Ms. Deirdre A. Cunnane, Chief Legal Officer & Treasurer (Age 53)
  • Dr. Angelika Fretzen Ph.D., Sr. VP of Product Devel.

When did Catabasis Pharmaceuticals IPO?

(CATB) raised $60 million in an initial public offering on Thursday, June 25th 2015. The company issued 4,300,000 shares at $13.00-$15.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.

Has Catabasis Pharmaceuticals been receiving favorable news coverage?

News stories about CATB stock have trended somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Catabasis Pharmaceuticals earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Catabasis Pharmaceuticals.

Who are Catabasis Pharmaceuticals' major shareholders?

Catabasis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Federated Investors Inc. PA (35.94%), Stonepine Capital Management LLC (8.27%) and Renaissance Technologies LLC (2.88%). View Institutional Ownership Trends for Catabasis Pharmaceuticals.

Which institutional investors are selling Catabasis Pharmaceuticals stock?

CATB stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Catabasis Pharmaceuticals.

Which institutional investors are buying Catabasis Pharmaceuticals stock?

CATB stock was acquired by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA and Stonepine Capital Management LLC. View Insider Buying and Selling for Catabasis Pharmaceuticals.

How do I buy shares of Catabasis Pharmaceuticals?

Shares of CATB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catabasis Pharmaceuticals' stock price today?

One share of CATB stock can currently be purchased for approximately $0.8142.

How big of a company is Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals has a market capitalization of $54.69 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-27,360,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Catabasis Pharmaceuticals employs 36 workers across the globe.

How can I contact Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals' mailing address is One Kendall Square Bldg. 1400E Suite B14202, Cambridge MA, 02139. The biotechnology company can be reached via phone at 617-349-1971 or via email at [email protected]


MarketBeat Community Rating for Catabasis Pharmaceuticals (NASDAQ CATB)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  252 (Vote Outperform)
Underperform Votes:  143 (Vote Underperform)
Total Votes:  395
MarketBeat's community ratings are surveys of what our community members think about Catabasis Pharmaceuticals and other stocks. Vote "Outperform" if you believe CATB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CATB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel